Clinical trial
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been…
NCT00003338 · Gilead Sciences, Industry · Unknown status
Key facts
| NCT number | NCT00003338 |
|---|---|
| Title | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma |
| Official title | The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Procedure, Radiation |
| Interventions | immunoscintigraphy, technetium Tc 99m epratuzumab |
| Enrollment | 60 |
| Start date | Mar 1, 1997 |
| First posted | Mar 12, 2004 |
| Last update posted | Aug 16, 2021 |
| Countries | Austria, Italy, Sweden, Switzerland, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: